NAD dependent 11β-hydroxysteroid dehydrogenase activity in human endometrium and endometrial tumors

Gynecologic and Obstetric Investigation

Volumn 62, Issue 2, 2006, Pages 103-107

  Manolis, Tsatsas ^a   Lee, Yi Chun ^a   Temkin, Sarah ^a   Hellman, Mira ^a   Nacharaju, Vijaya L ^a   Abulafia, Ovadia ^a,b  

^a SUNY Downstate Medical Center   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

11 hydroxysteroid dehydrogenase; Endometrial tumors; Glucocorticoids

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; GLUCOCORTICOID; ISOENZYME; NICOTINAMIDE ADENINE DINUCLEOTIDE;

ARTICLE; BENIGN TUMOR; CANCER GRADING; CARCINOSARCOMA; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CELL; ENDOMETRIUM TUMOR; ENZYME ACTIVITY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; METABOLITE; PRIORITY JOURNAL; STUDENT T TEST; UTERUS CARCINOMA; CANCER STAGING; CARCINOMA; COMPARATIVE STUDY; ENDOMETRIUM; ENZYMOLOGY; METABOLISM;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; CARCINOMA; CARCINOSARCOMA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; HYSTERECTOMY; NEOPLASM STAGING;

EID: 33746920390     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092856     Document Type: Article

References (29)

1. Hoffman LH, Davenport GR, Brash AR: Endometrial prostaglandins and phospholipase activity related to implantation in rabbits: effects of dexamethasone. Biol Reprod 1984;30:544-555.
2. Hicks JJ, Duran-Reyes G, Diaz-Flores M: Effect of dexamethasone as an inhibitor of implantation and embryo development in rat; lysosomal role. Contraception 1994;50:581-589.
3. Jo T, Terada N, Saji F, Tanizawa O: Inhibitory effects of estrogen, progesterone, androgen and glucocorticoid on death of neonatal mouse uterine epithelial cells induced to proliferate by estrogen. J Steroid Biochem Mol Biol 1993;46:25-32.
4. Bigsby RM: Progesterone and dexamethasone inhibition of estrogen induced synthesis of DNA and complement in rat uterine epithelium: effects of antiprogesterone compounds. J Steroid Biochem Mol Biol 1993;45:295-301.
5. Lakshmi V, Monder C: Purification and characterization of the corticosteroid 11 beta-dehydrogenase component of the rat liver 11 beta-hydroxysteroid dehydrogenase complex. Endocrinology 1988;123:2390-2398.
6. Lakshmi V, Nath N, Muneyyirci-Delale O: Characterization of 11 beta-hydroxysteroid dehydrogenase of human placenta: evidence for the existence of two species of 11 beta-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol 1993;45:391-397.
7. Burton PJ, Krozowski ZS, Waddell BJ: Immunolocalization of 11 beta-hydroxysteroid dehydrogenase types 1 and 2 in rat uterus: variation across the estrous cycle and regulation by estrogen and progesterone. Endocrinology 1998;139:376-382.
8. Yang K, Yu M: Evidence for distinct isoforms of 11 beta-hydroxysteroid dehydrogenase in the ovine liver and kidney. J Steroid Biochem Mol Biol 1994;49:245-250.
9. Rusvai E, Naray-Fejes-Toth A: A new isoform of 11 beta-hydroxysteroid dehydrogenase in aldosterone target cells. J Biol Chem 1993;268:10717-10720.
10. Brown RW, Chapman KE, Edwards CR, Seckl JR: Human placental 11 beta-hydroxylase: evidence for partial purification of a distinct NAD-dependent isoform. Endocrinology 1993;132:2614-2621.
11. Sun K, Yang K, Challis JR: Regulation of 11 beta-hydroxysteroid dehydrogenase type 2 by progesterone, estrogen, and the cyclic adenosine 5′-monophosphate pathway in cultured human placental and chorionic trophoblasts. Biol Reprod 1998;58:1379-1384.
12. Waddell BJ, Benediktsson R, Seckl JR: 11 Beta-hydroxysteroid dehydrogenase type 2 in the rat corpus luteum: induction of messenger ribonucleic acid expression and bioactivity co-incident with luteal regression. Endocrinology 1996;137:5386-5391.
13. Burton PJ, Dharmarajan AM. Hishe S, Waddell BJ: Induction of myometrial 11 beta-hydroxysteroid dehydrogenase type 1 messenger ribonucleic acid and protein expression late in rat pregnancy. Endocrinology 1996;137:5700-5706.
14. Smith RA, Salamonsen LA, Komesaroff PA, Li KX, Myles KM, Lawrence M, Krozowski Z: 11 Beta-hydroxysteroid dehydrogenase type II in the human endometrium: localization and activity during menstrual cycle. J Endocrinol Metab 1997;82:4252-4257.
15. Koyama K, Myles K, Smith R, Krozowski Z: Expression of the 11-beta hydroxysteroid dehydrogenase type II enzyme in breast tumors and modulation of activity and cell growth in PMC42 cells. J Steroid Biochem Mol Biol 2001;76:153-159.
16. Hundertmark S, Buhler H, Rudolf M, Weitzel HK, Ragosch V: Inhibition of 11 beta-hydroxysteroid dehydrogenase activity enhances the antiproliferative effect of glucocorticosteroids on MCF-7 and ZR-75-1 breast cancer cells. J Endocrinol 1997;155:171-180.
17. Koyama K, Krozowski Z: Modulation of 11 beta-hydroxysteroid dehydrogenase type 2 activity in Ishikawa cells is associated with changes in cellular proliferation. Mol Cell Endocrinol 2001;183:165-170.
18. Darnel AD, Archer TK, Yang K: Regulation of 11 beta-hydroxysteroid dehydrogenase type 2 by steroid hormones and epidermal growth factor in the Ishikawa human endometrial cell line. J Steroid Biochem Mol Biol 1999;70:203-210.
19. Suzuki S, Suzuki T, Tsubochi H, Koike K, Tateno H, Krozowski ZS, Sasano H: Expression of 11 beta-hydroxysteroid dehydrogenase type 2 and mineralocorticoid receptor in primary lung carcinomas. Anticancer Res 2000;20:323-328.
20. Takahashi K, Sasano H, Fukushima K, Hirasawa G, Miura H, Sasaki I, Matsuno S, Krozowski ZS, Nagura H: 11 Beta-hydroxysteroid dehydrogenase type II in human colon: a new marker of fetal development and differentiation in neoplasms. Anticancer Res 1998;18:3381-3388.
21. Mazzocchi G, Aragona F, Matendowicz LK, Gottardo L, Nussdorfer GG: Cortisol-secreting adrenal adenomas express 11 beta-hydroxysteroid dehydrogenase type 2 gene yet possess low 11 beta-HSD2 activity. J Investig Med 2001;49:191-194.
22. Rabbitt EH, Gittoes NJL, Stewart PM, Hewison M: 11 Beta-hydrosysteroid dehydrogenase, cell proliferation and malignancy. J Steroid Biochem Mol Biol 2003;85:415-421.
23. Baggia S, Albrecht ED, Pepe GJ: Regulation of 11 beta-hydroxysteroid dehydrogenase activity in the baboon placenta by estrogen. Endocrinology 1990;126:2742-2748.
24. Zelmanowicz A, Hildessheim A, Sherman ME, Sturgeon SR, Kurman RJ, Barrett RJ, Berman ML, Mortel R, Twiggs LB, Wilbanks GD, Brinton LA: Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors. Gynecol Oncol 1998;69:253-257.
25. George E, Lillemore TJ, Twiggs LB, Perrone T: Malignant mixed mullerian tumor versus high-grade endometrial carcinoma and aggressive variants of endometrial carcinoma: a comparative analysis of survival. Int J Gynecol Pathol 1995;14:39-44.
26. Moll UM, Chalas E, Auguste M, Meaney D, Chumas J: Uterine papillary serous carcinoma evolves via a p53-driven pathway. Hum Pathol 1996;27:1295-1300.
27. Umpierre SA, Burke TW, Tornos C, Ordonez N, Levenback C, Morris M: Immunocytochemical analysis of uterine papillary serous carcinomas for estrogen and progesterone receptors. Int J Gynecol Pathol 1994;13:127-130.
28. Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ: Endometrial intraepithelial carcinoma: a distinctive lesion specially associated with tumors displaying serous differentiation. Hum Pathol 1995;26:1260-1267.
29. Jazaeri AA, Numes KJ, Dalton MS, Xu M, Shupnik MA, Rice LW: Well-differenciated endometrial adenocarcinomas and poorly differenciated mixed mullerian tumors have altered ER and PR isoform expressions. Oncogene 2001;18:6965-6969.